Clinical Trial Update: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A randomized Phase 2/3 trial of BPN14770 in male adolescents aged 9 to under 18 with Fragile X syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• BPN14770

Snippet

Sponsor: Tetra Discovery Partners | Conditions: Fragile X Syndrome | Phase 2, Phase 3 | Status: COMPLETED